Ceftazidim hameln: Uses, Dosage & Side Effects

What Is Ceftazidim hameln and What Is It Used For?

Ceftazidim hameln contains ceftazidime as its active ingredient, a broad-spectrum, bactericidal beta-lactam antibiotic belonging to the cephalosporin class. Cephalosporins are among the most widely prescribed groups of antibiotics worldwide, and ceftazidime occupies a unique position within this class due to its exceptional activity against Pseudomonas aeruginosa – a gram-negative bacterium that is notoriously resistant to many other antibiotics and is a major cause of hospital-acquired infections, particularly in intensive care units, burn units, and among immunocompromised patients.

Ceftazidime exerts its antimicrobial effect by inhibiting bacterial cell wall synthesis. Like all beta-lactam antibiotics, it binds to penicillin-binding proteins (PBPs) located on the inner membrane of bacterial cells. These PBPs are enzymes essential for the final cross-linking step (transpeptidation) in peptidoglycan biosynthesis. By binding to PBP3 and PBP1a with high affinity, ceftazidime disrupts cell wall formation, leading to osmotic instability, cell lysis, and ultimately bacterial death. The bactericidal nature of ceftazidime – meaning it kills bacteria rather than merely stopping their growth – is an important clinical advantage, especially in patients with compromised immune systems who cannot rely on their own defenses to clear an infection.

An important feature of ceftazidime is its high degree of stability against many common beta-lactamases, which are enzymes produced by bacteria as a resistance mechanism against beta-lactam antibiotics. This stability allows ceftazidime to remain effective against many organisms that have developed resistance to earlier-generation cephalosporins and penicillins. However, it is important to note that ceftazidime is susceptible to hydrolysis by extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases when overproduced, and metallo-beta-lactamases (MBLs), which are increasingly prevalent in healthcare settings worldwide.

Ceftazidim hameln is approved and used for the treatment of a wide range of serious bacterial infections in both adults and children, including neonates. The specific indications include:

• Nosocomial pneumonia (hospital-acquired pneumonia): Ceftazidime is a first-line agent for ventilator-associated pneumonia and other hospital-acquired lower respiratory tract infections, especially when Pseudomonas aeruginosa is suspected or confirmed as the causative pathogen.
• Bronchopulmonary infections in cystic fibrosis: Patients with cystic fibrosis are particularly susceptible to chronic Pseudomonas aeruginosa colonization and recurrent pulmonary exacerbations. Ceftazidime has been a cornerstone of anti-pseudomonal therapy in this population for decades.
• Bacterial meningitis: Ceftazidime achieves adequate concentrations in the cerebrospinal fluid (CSF) when the meninges are inflamed, making it suitable for the treatment of gram-negative meningitis, including that caused by Pseudomonas species.
• Chronic suppurative otitis media (ear infection): Severe or complicated ear infections caused by gram-negative bacteria may require parenteral ceftazidime therapy.
• Complicated urinary tract infections: Including pyelonephritis (kidney infection) caused by susceptible organisms, particularly when oral antibiotics are insufficient.
• Complicated skin and soft tissue infections: Including cellulitis, wound infections, and infections following surgery or trauma when gram-negative coverage is needed.
• Complicated intra-abdominal infections: Typically used in combination with an agent effective against anaerobic bacteria (e.g., metronidazole) for peritonitis and other abdominal infections.
• Bone and joint infections: Including osteomyelitis and septic arthritis caused by susceptible gram-negative organisms.
• Peritonitis associated with dialysis: Used in patients on continuous ambulatory peritoneal dialysis (CAPD) who develop peritonitis.
• Bacteremia / septicemia: When serious bloodstream infections are caused by susceptible bacteria.
• Febrile neutropenia: Ceftazidime is used as empirical monotherapy or in combination with other antimicrobials for the management of suspected bacterial infections in immunocompromised patients with fever and low white blood cell counts, a common and potentially life-threatening complication of cancer chemotherapy.

What Should You Know Before Taking Ceftazidim hameln?

Contraindications

Ceftazidim hameln must not be used if you have a known severe hypersensitivity (allergic reaction) to ceftazidime, to any other cephalosporin antibiotic, or to any of the excipients contained in the product. The most critical contraindication relates to patients who have experienced a previous immediate or severe hypersensitivity reaction (such as anaphylaxis) to any beta-lactam antibiotic, including penicillins, carbapenems, or monobactams. In such patients, the risk of a life-threatening cross-allergic reaction is significant and ceftazidime should not be administered.

It is essential that healthcare professionals take a thorough allergy history before initiating ceftazidime therapy. Patients should report any previous reactions to antibiotics, even if the reaction occurred many years ago. A history of mild, non-immediate skin rash to penicillin does not necessarily preclude the use of ceftazidime, but the decision must be made by a physician who can assess the risk and ensure appropriate monitoring and emergency equipment are available.

Warnings and Precautions

Several important precautions must be considered before and during treatment with ceftazidim hameln. Your healthcare provider will evaluate these carefully:

Renal impairment: Ceftazidime is excreted almost entirely by the kidneys. In patients with reduced kidney function (renal impairment), the drug is cleared more slowly, leading to higher blood levels and an increased risk of adverse effects, including neurotoxicity manifesting as encephalopathy, seizures, myoclonus, and asterixis. Dosage must be carefully adjusted based on the degree of renal impairment, typically guided by creatinine clearance (CrCl) measurements. Regular monitoring of renal function is recommended during treatment.

Clostridioides difficile-associated diarrhea (CDAD): Antibiotic-associated diarrhea and colitis, including pseudomembranous colitis caused by Clostridioides difficile (formerly Clostridium difficile), have been reported with nearly all antibacterial agents, including ceftazidime. The severity can range from mild diarrhea to fulminant, life-threatening colitis. Antibiotics alter the normal flora of the colon, allowing C. difficile to overgrow and produce toxins that cause inflammation and tissue damage. If significant diarrhea develops during or after treatment, CDAD must be considered. If confirmed, the offending antibiotic should be discontinued (unless it is being used to treat a life-threatening infection) and appropriate therapy initiated.

Superinfection with resistant organisms: Prolonged use of ceftazidime, as with any antibiotic, may result in the overgrowth of non-susceptible organisms, including fungi (such as Candida species) and resistant bacteria (such as Enterococcus species or methicillin-resistant Staphylococcus aureus). Patients should be monitored for signs of superinfection and appropriate treatment initiated if it occurs.

Concurrent use with nephrotoxic drugs: Ceftazidime should be used with caution in combination with nephrotoxic agents such as aminoglycoside antibiotics (e.g., gentamicin, tobramycin, amikacin), loop diuretics (e.g., furosemide), or other drugs known to impair kidney function. Concurrent use may increase the risk of renal toxicity, and renal function should be monitored more frequently.

Sodium content: Each gram of ceftazidime contains approximately 2.3 mmol (approximately 52 mg) of sodium. This should be taken into consideration for patients on a controlled sodium diet or those with conditions such as heart failure, hypertension, or renal impairment where sodium loading could be harmful, particularly when high doses are being administered.

Interference with laboratory tests: Ceftazidime may cause a false-positive result in urine glucose tests that use copper reduction methods (e.g., Clinitest). Enzymatic glucose oxidase methods are not affected and should be used for glucose monitoring during ceftazidime treatment. Additionally, a positive Coombs test (direct antiglobulin test) may occur during treatment; this is common with cephalosporins and does not necessarily indicate hemolysis, but it may interfere with blood cross-matching procedures.

Pregnancy and Breastfeeding

The safety of ceftazidime use during pregnancy has not been established through large, well-controlled clinical trials. Animal reproductive studies have not demonstrated evidence of teratogenicity or impaired fertility, but animal studies are not always predictive of human response. Ceftazidime crosses the placenta and is present in amniotic fluid. As a general principle, ceftazidime should only be used during pregnancy when the potential benefit to the mother outweighs the potential risk to the fetus. In clinical practice, cephalosporins as a class are generally considered to have a favorable safety profile in pregnancy, and ceftazidime has been used extensively in pregnant women when serious infections require treatment.

Ceftazidime is excreted in human breast milk in low concentrations. While the amount reaching the nursing infant is considered small, there is a theoretical risk of sensitization, alteration of the infant’s intestinal flora, or development of Candida infection. The decision to continue or discontinue breastfeeding during ceftazidime treatment should be made by the treating physician, weighing the benefits of breastfeeding against the potential risks to the infant and the importance of the antibiotic treatment to the mother.

How Does Ceftazidim hameln Interact with Other Drugs?

Drug interactions with ceftazidime are fewer in number and generally less clinically significant than with many other classes of antibiotics. This is because ceftazidime is not metabolized by the liver (it undergoes no hepatic biotransformation) and is excreted unchanged by the kidneys through glomerular filtration. It does not inhibit or induce cytochrome P450 enzymes, which are responsible for the metabolism of a large proportion of other drugs. However, several interactions are important to recognize and manage in clinical practice.

Your healthcare team will review all your current medications, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins, before starting ceftazidime treatment. Below are the most important known interactions:

Major Interactions

Minor Interactions

What Is the Correct Dosage of Ceftazidim hameln?

The dosage of Ceftazidim hameln depends on the type, severity, and location of the infection, the susceptibility of the causative organism, the patient’s age, body weight, and renal function. All doses below refer to the equivalent amount of ceftazidime (base). The drug is administered by intravenous (IV) injection over 3–5 minutes, by IV infusion over 15–30 minutes, or by deep intramuscular (IM) injection into a large muscle (the upper outer quadrant of the gluteus maximus or the lateral aspect of the thigh). IV administration is preferred for severe infections and for patients with septicemia, meningitis, or other critical illness.

Adults

For the most serious and life-threatening infections, the maximum recommended daily dose in adults with normal kidney function is 9 g (typically given as 3 g every 8 hours or 2 g every 8 hours). The duration of treatment depends on the clinical response and the nature of the infection but typically ranges from 7 to 14 days. Some infections, such as bone and joint infections, may require longer courses of 4 to 6 weeks or more.

Children

Elderly

In elderly patients, no dose adjustment is needed based on age alone. However, many elderly patients have some degree of age-related decline in renal function, which may not be reflected by serum creatinine levels. Creatinine clearance should be estimated (using the Cockcroft-Gault formula or similar) and the dose adjusted accordingly if impaired. Elderly patients may also be more susceptible to certain adverse effects, including neurotoxicity (confusion, myoclonus, seizures) at therapeutic or slightly elevated drug levels.

Dosage in Renal Impairment

Missed Dose

Because ceftazidime is administered in a clinical setting by healthcare professionals, missed doses are uncommon. If a dose is delayed or missed, it should be given as soon as it is recognized, and subsequent doses should be rescheduled to maintain the prescribed interval. The dose should not be doubled to make up for a missed dose. If you are receiving ceftazidime as an outpatient (e.g., through outpatient parenteral antibiotic therapy, OPAT), contact your healthcare provider or infusion nurse promptly if you miss a scheduled dose to receive guidance on when to administer the next dose.

Overdose

Overdosage with ceftazidime can lead to neurological sequelae including encephalopathy, seizures, coma, and asterixis (flapping tremor), particularly in patients with renal impairment where drug accumulation is accelerated. Other symptoms may include pain, inflammation, and phlebitis at the injection site. Laboratory abnormalities may include elevated creatinine, blood urea nitrogen (BUN), liver enzymes, and bilirubin, as well as a positive Coombs test, thrombocytosis, thrombocytopenia, leukopenia, and eosinophilia.

Treatment of overdose is supportive. There is no specific antidote for ceftazidime. Serum levels of ceftazidime can be reduced by hemodialysis or peritoneal dialysis, and these may be considered in cases of severe overdose, especially when the patient has significantly impaired renal function. In a healthcare setting, the patient will be monitored for seizure activity, renal function, and other vital parameters, and supportive care including airway management and anticonvulsant therapy will be provided as needed.

What Are the Side Effects of Ceftazidim hameln?

Like all medicines, ceftazidime can cause side effects, although not everybody gets them. Most side effects are mild and transient, resolving after the treatment is completed. However, some side effects can be serious and require immediate medical attention. The frequency categories below are based on clinical trial data and post-marketing surveillance, and are defined according to international convention:

The risk of neurotoxicity is significantly increased in patients with impaired renal function who do not receive appropriate dose reductions. Neurological symptoms have included tremors, myoclonus (involuntary muscle jerking), seizures, encephalopathy (altered consciousness, confusion), and non-convulsive status epilepticus. These symptoms are typically reversible upon dose reduction or discontinuation of the drug. Healthcare providers should be vigilant for early signs of neurotoxicity, particularly in elderly patients and those in intensive care who may have fluctuating renal function.

Gastrointestinal side effects are the most commonly reported adverse reactions. Diarrhea is usually mild and self-limiting, but if severe, watery, or bloody diarrhea develops – especially if accompanied by abdominal cramps, fever, or malaise – Clostridioides difficile infection should be suspected and investigated. Patients should be advised not to take anti-diarrheal medications without consulting their healthcare provider, as these may mask the symptoms of pseudomembranous colitis.

Hematological changes observed during ceftazidime treatment include eosinophilia (the most common blood abnormality), thrombocytosis, leukopenia, neutropenia, agranulocytosis, and lymphocytosis. These changes are generally mild, transient, and reversible. A positive direct Coombs test develops in approximately 5% of patients receiving ceftazidime; this is a class effect of cephalosporins and does not usually indicate clinically significant hemolysis, but it may interfere with blood cross-matching procedures. Rare cases of Coombs-positive hemolytic anemia have been reported.

How Should You Store Ceftazidim hameln?

Proper storage of Ceftazidim hameln is essential to ensure the product remains safe and effective. As this medication is typically handled by healthcare professionals in clinical settings, storage requirements are generally managed by the pharmacy or nursing department. However, patients receiving treatment at home through outpatient parenteral antibiotic therapy (OPAT) programs should be aware of these requirements.

Unopened vials: Store the dry powder vials below 25°C (77°F). Protect from light. Keep the vials in the outer carton until ready for use. Do not freeze the dry powder. The shelf life of the unopened product is specified on the packaging – do not use after the expiry date printed on the vial and carton.

Reconstituted solution: After reconstitution with Water for Injections or another appropriate diluent, the solution should be used as soon as practicable. Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2–8°C (refrigerated) and up to 8 hours at 25°C or below, depending on the diluent used. From a microbiological perspective, the product should ideally be used immediately after reconstitution. If not used immediately, in-use storage times and conditions are the responsibility of the user.

The freshly reconstituted solution may range from light yellow to amber in color – this variation in color does not indicate a loss of potency. However, do not use the solution if it appears very dark, turbid, or contains visible particulate matter. Solutions containing carbon dioxide bubbles after reconstitution can be used safely – these will dissipate over time.

Keep all medicines out of the reach and sight of children. Do not dispose of unused medication by pouring it down the drain or throwing it in household waste. Ask your pharmacist about the proper disposal of medicines you no longer need. These measures help protect the environment.

What Does Ceftazidim hameln Contain?

Understanding the exact composition of Ceftazidim hameln is important for healthcare professionals managing patients with specific drug sensitivities, sodium restrictions, or other dietary and medical considerations. The formulation is intentionally simple, as befitting an injectable antibiotic.

Active ingredient: Each vial contains ceftazidime 1 g (equivalent to ceftazidime pentahydrate). Ceftazidime is a semi-synthetic cephalosporin antibiotic derived from 7-aminocephalosporanic acid (7-ACA). Its molecular formula is C₂₂H₂₂N₆O₇S₂, and it has a molecular weight of approximately 546.6 g/mol (anhydrous form). The pentahydrate form is used in the pharmaceutical formulation, which adds five water molecules to the crystal structure for stability during storage.

Other ingredient: Sodium carbonate (anhydrous) is included as a buffering and solubility-enhancing agent. It adjusts the pH of the reconstituted solution and facilitates the dissolution of the active substance during reconstitution. Sodium carbonate contributes to the sodium content of the product.

Sodium content: Each gram of ceftazidime contains approximately 2.3 mmol (approximately 52 mg) of sodium. For a patient receiving the maximum dose of 6 g/day, this equates to approximately 312 mg of sodium daily from the medication alone. This is a clinically relevant consideration for patients on sodium-restricted diets, those with congestive heart failure, hypertension, or conditions associated with fluid retention. Healthcare providers should factor this additional sodium intake into the patient’s overall fluid and electrolyte management plan.

Appearance: Before reconstitution, Ceftazidim hameln is a white to off-white crystalline powder. After reconstitution, the solution is clear and ranges from light yellow to amber in color. The product does not contain preservatives, latex, or gluten.

References and Sources

All medical information in this article is based on peer-reviewed scientific literature, international clinical guidelines, and regulatory authority documentation. The following sources were used:

1. European Medicines Agency (EMA). Summary of Product Characteristics: Ceftazidime. EMA, 2024. Accessed January 2026.
2. World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). WHO, 2023. Ceftazidime is listed as an essential antibiotic for hospital use.
3. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–1052. doi:10.2165/00003495-200767070-00006
4. Richards DM, Brogden RN. Ceftazidime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985;29(2):105–161. doi:10.2165/00003495-198529020-00002
5. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters, Version 14.0, 2024.
6. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, M100, 34th edition, 2024.
7. Infectious Diseases Society of America (IDSA). Mermel LA, et al. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection. Clin Infect Dis. 2009;49(1):1–45. doi:10.1086/599376
8. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. IDSA 2023 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2023. doi:10.1093/cid/ciad428
9. British National Formulary (BNF). Ceftazidime monograph. NICE/BNF, 2024. Accessed January 2026.
10. U.S. Food and Drug Administration (FDA). Fortaz (ceftazidime for injection) Prescribing Information. FDA, 2024.
11. Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. J Pediatr. 2009;155(6 Suppl):S73–S93. doi:10.1016/j.jpeds.2009.09.001

All cited references are peer-reviewed or from recognized international regulatory and guideline bodies (WHO, EMA, FDA, IDSA, EUCAST, BNF). Evidence level: 1A for supported indications based on systematic reviews and randomized controlled trials. Content follows the GRADE evidence framework.

Editorial Team

This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in infectious disease, microbiology, and clinical pharmacology.

All content follows the GRADE evidence framework and is reviewed according to international medical guidelines. iMedic receives no commercial funding from pharmaceutical companies.